[["BRAF inhibitors", "are approved by", "the US Food and Drug Administration"], ["vemurafenib and dabrafenib", "demonstrate", "superior efficacy in patients with BRAF-mutant melanomas"], ["vemurafenib and dabrafenib", "have limited efficacy in", "BRAF-mutant colorectal cancer"], ["little is known", "regarding", "BRAF inhibitors in thyroid cancer"], ["initial reports", "suggest", "response rates of approximately 30-40% in BRAF-mutant papillary thyroid cancer"], ["this review", "discusses", "BRAF inhibitors in the context of thyroid cancer"], ["BRAF inhibitors", "are associated with", "toxicities"], ["the management of vemurafenib and dabrafenib toxicities", "is applicable across", "all tumor types"], ["the management of toxicities", "may serve as", "a practical guide to the use of BRAF inhibitors"]]